Clinical Research Directory
Browse clinical research sites, groups, and studies.
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Sponsor: Consorci Sanitari de Terrassa
Summary
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
Official title: Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
3000
Start Date
2020-03-01
Completion Date
2028-02-24
Last Updated
2026-03-25
Healthy Volunteers
No
Interventions
Antihistamine
No intervention is performed. We propose an observational study.
Amantadine
No intervention is performed. We propose an observational study
ACEI
No intervention is performed. We propose an observational study.
ARB
No intervention is performed. We propose an observational study.
Influenza vaccine and COVID
No intervention is performed. We propose an observational study.
Locations (1)
Hospital de Terrassa
Terrassa, Barcelona, Spain